Clinical trials recruiting for TNBC - Triple-Negative Breast Cancer
35
Recruiting trials
33
US states with sites
10
Countries
0%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| New York | 7 |
| Texas | 7 |
| California | 5 |
| Florida | 5 |
| Ohio | 5 |
| New Jersey | 4 |
| Alabama | 3 |
| Connecticut | 3 |
| Maryland | 3 |
| Michigan | 3 |
| Missouri | 3 |
| Pennsylvania | 3 |
Top cities
New York, New York 5Los Angeles, California 4Cleveland, Ohio 3Houston, Texas 3Nashville, Tennessee 3New Haven, Connecticut 3Philadelphia, Pennsylvania 3Tampa, Florida 3Austin, Texas 2Birmingham, Alabama 2
Self-screener
Recruiting trials
- 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
- A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer
- A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
- A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance
- A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
- A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC
- A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
- Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
- Estrogen Receptor (ER) PET/CT Imaging in Breast Cancer
- Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK
- LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer
- MRI-Guided Neoadjuvant Treatment De-Escalation in Stage II-III TNBC
- Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
- Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)
- Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)
- Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer
- Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer
- Neoadjuvant Toripalimab Plus SBRT for Chemo-Resistant Triple-Negative Breast Cancer
- PSMA-PET/CT to Assess the Expression of Specific Membrane Antigen (PSMA) in Patients With Progressive Triple-negative Breast Cancer.
- Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer
- Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
- QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC
- QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride and Nab-Paclitaxel as First-Line Treatment for Advanced Triple-Negative Breast Cancer
- Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer
- Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation
- Role of the Immune Environment in Response to Therapy in Breast Cancer
- SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC
- Study of AVZO-021 in Patients With Advanced Solid Tumors
- Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM.
- The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study
- Trop-2 Targeted PET Probes in Advanced TNBC
Related conditions
Trials recruiting for TNBC - Triple-Negative Breast Cancer often also study these conditions. Each links to its own recruiting-trial list.
Breast cancer 2239HER2-negative Breast Cancer 57Endometrial cancer 68Triple-negative breast cancer 138Lung cancer 2180Colorectal cancer 1359Small Cell Lung Cancer ( SCLC ) 29SCLC 13Non-small cell lung cancer 507Metastatic breast cancer 131
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for TNBC - Triple-Negative Breast Cancer trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.